2022 revenue: EUR 35.3 m - 2023 targets and perspectives Read more about 2022 revenue: EUR 35.3 m - 2023 targets and perspectives
2022 revenue: EUR 35.8 m - 2023 targets and perspectives Read more about 2022 revenue: EUR 35.8 m - 2023 targets and perspectives
Update on progress regarding Multi-Project-Wafer ("MPW") Read more about Update on progress regarding Multi-Project-Wafer ("MPW")
Havyard Leirvik win important contract with a new customer Read more about Havyard Leirvik win important contract with a new customer
Transactions made under the repurchase program for Eqva ASA Read more about Transactions made under the repurchase program for Eqva ASA
Transactions made under the repurchase program for Eqva ASA Read more about Transactions made under the repurchase program for Eqva ASA
MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test Read more about MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia) Read more about Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)